TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06403449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-delivered guided written exposure therapy-revised version
Description: Group-Delivered guided WET-R (G-WET) is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete.The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting-List (WL) condition
Description: Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
Study: NCT05812885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Active TENS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: Active TENS
Study: NCT06563960

Intervention type: OTHER
Group type: OTHER
Intervention: carbonated water
Description: Participants will drink carbonated water during videofluoroscopy.
Study: NCT06282341

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Race: Simulated marathon
Description: Participants will take part in a race: simulated marathon. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Race: Simulated trail
Description: Participants will take part in a race: simulated trail. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Race: Trail in nature
Description: Participants will take part in a race: trail in nature. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
Study: NCT05324241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat Microcapsules
Description: Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat Microcapsules
Description: Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.
Study: NCT05716451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device-assisted mobilisation with the sit/stand stabilizer Liana
Description: Non-invasive device-assisted mobilisation with LIANA
Study: NCT05834907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circle of Security Parenting
Description: COS-P is an attachment-based, home visiting intervention intended to supporting parents in serving as a secure base from which their children can explore the world, and to which their children can return in times of distress (Bowlby, 1988). Such secure base parenting increases the likelihood of children's secure attachment. COS-P also targets parental responses to children's expression of their needs (e.g., crying), and is designed to help parents understand the ways in which their own (parental) dysregulated emotional, physiological, and behavioral responses to children's emotions and behaviors can limit their responsiveness to their children's attachment needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Little Talks
Description: Little Talks is an early literacy home visiting intervention developed for low-income, racial and ethnic minority infants and toddlers, and has been tested in Early Head Start contexts (Manz et al., 2016; Manz et al. 2017). Little Talks uses book sharing to promote early literacy and has been adapted in both English and Spanish. The intervention utilizes modular treatments during home visits, teaching parents how to facilitate language interactions with their children through book sharing. Age appropriate books are given to parents to share with their children during the intervention.
Study: NCT04920903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR588
Description: Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
Study: NCT05322629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP adherence biofeedback
Description: Services for women in the intervention arm includes bio-feedback adherence counseling based on urine lateral flow assays of tenofovir to measure adherence with rapid PrEP delivery .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care counseling
Description: Adherence counseling based on self report and following national guidelines
Study: NCT05246033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TransCon CNP
Description: Weekly subcutaneously injection of placebo.
Study: NCT06331520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netupitant / Palonosetron Oral Capsule [Akynzeo]
Description: Akynzeo is the fixed-combination antiemetic comprising netupitant (neurokinin-1 receptor antagonist \[NK1 RA\]) and palonosetron (5-hydroxytryptamine-3 receptor antagonist \[5-HT3 RA\]).
Study: NCT05218044

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoablation
Description: The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
Study: NCT06331520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant / Palonosetron Oral Capsule [Akynzeo]
Description: Akynzeo is the fixed-combination antiemetic comprising netupitant (neurokinin-1 receptor antagonist \[NK1 RA\]) and palonosetron (5-hydroxytryptamine-3 receptor antagonist \[5-HT3 RA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netupitant / Palonosetron Oral Capsule [Akynzeo]
Description: Akynzeo is the fixed-combination antiemetic comprising netupitant (neurokinin-1 receptor antagonist \[NK1 RA\]) and palonosetron (5-hydroxytryptamine-3 receptor antagonist \[5-HT3 RA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. It belongs to the 2nd generation antipsychotics, its mechanism of action ranks among multireceptor antagonists (MARTA); it affects the dopamine, serotonin, adrenaline, histamine, and muscarinic systems.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. It belongs to the 2nd generation antipsychotics, its mechanism of action ranks among multireceptor antagonists (MARTA); it affects the dopamine, serotonin, adrenaline, histamine, and muscarinic systems.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. It belongs to the 2nd generation antipsychotics, its mechanism of action ranks among multireceptor antagonists (MARTA); it affects the dopamine, serotonin, adrenaline, histamine, and muscarinic systems.
Study: NCT06195891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Computed Tomography
Description: Undergo DECT/MRI scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo DECT/MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow and Lymphoid Irradiation
Description: Undergo TMLI
Study: NCT06331520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: synthetic glucocorticoids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: synthetic glucocorticoids
Study: NCT05061030

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: the ATMP Protrans
Description: Protrans consists of Wharton's jelly derived mesenchymal stromal cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: the ATMP Protrans
Description: Protrans consists of Wharton's jelly derived mesenchymal stromal cells
Study: NCT06264167

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-resolution bilateral groin ultrasound surveillance
Description: Participants in the Interventional Treatment (serial ultrasounds) group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, follow-up appointments occur bi-monthly for 12 months, involving a clinical examination and groin ultrasound. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
Study: NCT05075759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive personalized clinician-led self-management telehealth sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive personalized goal setting for daily steps and activity and dietary goals
Study: NCT06182423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS-CI (Support, Training, and Education for Pain Self-management- Cognitively Inclusive version)
Description: This intervention is a community health worker (CHW)-led chronic pain self-management program designed for older adults with chronic pain and mild to moderate cognitive impairment. It is a 7-week intervention that includes two primary components: a website that includes brief instructional videos on pain management skills as well as testimonials from individuals living with the two target health conditions; and weekly telephone sessions with a CHW to support and motivate participants in setting goals related to pain management. Reminder strategies and content addressing pain management challenges related to cognitive impairment are incorporated throughout. Participants may choose to work with a care partner during intervention activities.
Study: NCT05068193

Intervention type: DRUG
Group type: OTHER
Intervention: BR2008-1 (R)
Description: After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.
Study: NCT05075759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Remote sessions with a health coach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study: NCT05506254

Intervention type: DRUG
Intervention: hLB-001
Description: hLB-001 gene therapy
Study: NCT06173466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride combined with dexamethasone
Description: Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
Study: NCT05904028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
Description: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
Description: Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
Study: NCT05348096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose ibrutinib
Description: Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
Study: NCT06019299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Practice
Description: Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
Study: NCT06540170

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A personalised self-care support program
Description: A personalized care program consists of three 30-minute face-to-face sessions (once every 1-2 weeks) after patients' routine wound dressings to enhance self-efficacy, support emotional adjustments, and DFU self-care.
Study: NCT05465304

Intervention type: DRUG
Intervention: Azithromycin
Description: The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated

Intervention type: DRUG
Intervention: Azithromycin
Description: The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
Study: NCT05703685

Intervention type: RADIATION
Group type: OTHER
Intervention: Lung scan
Description: Immediately after the brain scan

Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Oral administration of apremilast
Study: NCT06019299

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Practice
Description: Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
Study: NCT05991999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Master swimmers will be taught iliopsoas, sternocleidomastoid and pectoralis major stretching exercises as stretching exercises. Participants will stretch daily for 3 repetitions, each stretching for 20 seconds.~Participants will continue their swimming training 2 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Participants continued their swimming training 2 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Participants continued their swimming training 2 days a week.
Study: NCT06105333

Intervention type: PROCEDURE
Intervention: standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline
Description: CrSO2 (Cerebral regional oxygen saturation) monitoring was visible to the clinical team with the same SpO2 target as in the control group. If SpO2 (oxygen saturation) remained between the 10th and 90th centiles and within local limits, and crSO2 was \<10th centile according to published reference ranges, FiO2 (fraction of inspired oxygen) was increased by 10-20% every 60 seconds or respiratory support was started or increased. If crSO2 remained \>10th centile for \>60 seconds or if rSO2 was \>90th centile,FiO2 was reduced by 10-20% or respiratory support was adjusted accordingly. If there was a history of blood loss or clinical signs of blood loss, intravenous fluids (10 mL/kg) were considered.
Study: NCT04435236

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical ESP block
Description: Cervical ESP block will be performed as described by Elsharkawy at al. (7). ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cervical ESP block
Description: Cervical ESP block will be performed as described by Elsharkawy at al. (7). ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
Study: NCT04971447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gender affirming hormonal treatment in transgender men
Description: testosterone enanthate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gender affirming hormonal treatment in transgender women
Description: GnRH agonists + estrogen
Study: NCT06081049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT05068193

Intervention type: DRUG
Group type: OTHER
Intervention: BR2008-1 (R)
Description: After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.

Intervention type: DRUG
Group type: OTHER
Intervention: BR2008 (T)
Description: After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.

Intervention type: DRUG
Group type: OTHER
Intervention: BR2008 (T)
Description: After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.
Study: NCT04888234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ru-Yi-Jin-Huang Powder
Description: Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
Study: NCT05759117

Intervention type: PROCEDURE
Intervention: thoracentesis
Description: A type of pleural procedure that will yield pleural fluid for subsequent analysis
Study: NCT05462730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
Study: NCT05828121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POINT1
Description: Receiving treatment
Study: NCT05128370

Intervention type: OTHER
Intervention: Visual observation of arm swing during walking
Description: The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
Study: NCT05790421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Muscle Energy Technique
Description: Starting from the preparation position, at the restriction barrier, the patient is asked to exert a small effort (no more than 20% of available strength) towards plantarflexion, against unyielding resistance, with appropriate breathing. The patient produces isometric effort contracts either gastrocnemius or soleus (depending on whether the knee is unflexed or flexed). This contraction is held for 7-10 seconds together with a held breath. The exercise was repeated until the full range of movement was obtained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Program
Description: Graduated active resisted range of motion exercises for both UL and LL and graduated gait training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Program
Description: Graduated active resisted range of motion exercises for both UL and LL and graduated gait training
Study: NCT04704141

Intervention type: DRUG
Intervention: Hormone replacement therapy
Description: A hormone replacement regimen using any medication of a number of standard treatment options